Dose-effect Relationship of Tai Chi on Health Promotion in Different Age Groups
NCT06307483, Completed, Beijing Sport University
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Dose-effect Relationship of Tai Chi on Health Promotion in Different Age Groups | ClinicalTrials.gov |
| NCT number | NCT06307483 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 499 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Beijing Sport University | ClinicalTrials.gov |
| Conditions | Sleep Disorder, Cardiovascular Diseases, Hypertension, Cognitive Impairment, Metabolic Disease | ClinicalTrials.gov |
| Interventions | Taichi group, Exercise group | ClinicalTrials.gov |
| First posted | 2024-03-12 | ClinicalTrials.gov |
| Last updated | 2024-03-26 | ClinicalTrials.gov |
Registered outcomes 27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Pittsburgh Sleep Quality Index | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | With subscale scores ranging from 0 to 3, the PSQI assesses subjective sleep quality in the previous month and consists of seven items (sleep duration, sleep latency, sleeping medications, sleep disturbance, daytime dysfunction, sleep quality, and sleep efficiency). The total score of the PSQI, ranging from 0 to 21, is the sum of subscale scores, and the higher the scores, the lower the subjective quality of sleep. | ClinicalTrials.gov |
| Primary | Heart rate variability (HRV) | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | HRV, a non-invasive method used to evaluate the autonomic nervous system modulation on the cardiac sinus node, describes the oscillations between consecutive electrocardiogram R-R intervals. High levels of HRV indices are generally signs of efficient autonomic mechanisms that characterise a healthy individual, while low or reduced HRV often show an autonomic nervous system malfunction and may imply health impairment. | ClinicalTrials.gov |
| Primary | Flow-mediated dilation (FMD) | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | Flow-mediated dilation (FMD) can assess endothelium-dependent vasodilation, evaluating vascular elasticity and dilation function. Its mechanism involves inducing reactive hyperemia, increasing arterial blood flow, leading to elevated shear stress on the vessel wall, prompting endothelial cells to release NO, resulting in vasodilation. A normal FMD value is ≥7%; values \<4% indicate endothelial dysfunction. | ClinicalTrials.gov |
| Primary | Cardiac Output (CO) | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | Cardiac Output (CO) is a key indicator in echocardiographic examinations, used to measure the total volume of blood pumped by the heart per minute. This parameter reflects the efficiency of the heart's pumping action and the status of systemic blood circulation. The measurement of Cardiac Output is based on the volume of blood ejected by the heart with each beat (stroke volume) and the number of heartbeats per minute. Cardiac Output is typically expressed in liters per minute (L/min). | ClinicalTrials.gov |
| Primary | Intima-Media Thickness (IMT) | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | Intima-Media Thickness (IMT) is a significant indicator measured through carotid ultrasound examination, used to assess the thickness of the carotid artery wall. The measurement of IMT focuses on the distance between the intima and media layers of the carotid artery, serving as a key indicator of early changes in atherosclerosis. | ClinicalTrials.gov |
| Primary | The Berg Balance Scale（BBS） | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | The BBS scale evaluates an individual's ability to maintain their balance while performing functional activities. It includes 14 items and each section is scored between 0 (worst) and 4 (best), and measures level of dependence/independence in positions such as standing from sitting, standing with feet together, standing in full balance position, balancing on one leg, as well as ability to change positions. High BBS score indicates good balance. Participants are classifed based on BBS score as high fall risk, balance disorder (0-20 points), moderate fall risk, acceptable balance (21-40 points), and low fall risk, good balance (41-56 points) | ClinicalTrials.gov |
| Primary | The 30-s Chair Stand Test | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | In the 30-s CST, which assesses dynamic balance and physical ftness, the individual sits in the middle of a chair with seat height of 43 cm, with a straight back, feet fat on the foor, and arms crossed over the chest with hands at shoulder level. The test starts with the subject in this position at the "go" command. The number of times the patient rises to a full standing position without assistance in 30 s is recorded as the test score. A score of 5 indicates strength and 10 indicates both strength and endurance | ClinicalTrials.gov |
| Primary | Lower limb muscle strength test | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | Using the micro FET3 (HOGGAN, USA) to test lower limb muscle strength. The main muscles tested include the tibialis anterior, triceps surae, quadriceps femoris, hamstrings, and iliopsoas. Each muscle is tested twice, and the maximum value is recorded | ClinicalTrials.gov |
| Secondary | Body Fat Percentage | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | Body fat percentage refers to the proportion of body fat weight in the total body weight of the human body, which reflects the amount of fat content in the human body. Normal adult body fat percentage should be kept in a certain range. A high body fat percentage can be considered a criterion for obesity. | ClinicalTrials.gov |
| Secondary | Finger-Ring Test | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | The finger-ring test is an effective alternative to calf circumference, in which people encircle the thickest part of the non-dominant calf with the index fingers and thumbs of both hands, and are at an increased risk of developing sarcopenia if the measured calf fits just right or is turned smaller than their fingers. | ClinicalTrials.gov |
| Secondary | Hand Grip Strength | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | Grip strength is mainly a test of the degree of development of the upper limb muscle groups, testing the subject's forearm and hand muscle strength, reflecting the level of development of the human body's upper limb strength of an indicator. | ClinicalTrials.gov |
| Secondary | Upper and Lower Body Flexibility | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | Flexibility is often considered one of the most important components of physical fitness. It is often used to describe the range of motion of a single joint or a series of joints. Among the most commonly reported simple field tests of flexibility of the lower extremity have been sit and reach (SR) test. | ClinicalTrials.gov |
| Secondary | The SARC-F scale | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | The SARC-F scale is a screening tool for muscle wasting disorders that has been developed in recent years to provide a rapid assessment of muscle strength and function without the need to rely on expensive instrumentation to measure muscle mass. SARC-F ≥ 4 is defined as sarcopenia. The questions of SARC-F cover physical functions targeting sarcopenia or initial presentation for sarcopenia. | ClinicalTrials.gov |
| Secondary | Shape Trail Test (STT) | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | The Trail Making Test (TMT) scoring is expressed in terms of the time in seconds for Part A and Part B of the test. Some examiners also calculate a Trails B/Trails A ratio. The TMT is one of the most sensitive and popular tests for identifying mild cognitive impairment and mild dementia. It measures the speed for attention, sequencing, mental flexibility, and of visual search and motor function, mainly reflecting the ability of "set shifting".In China, the Shape Trail Test (STT) is more widely used. The STT was developed with the intent to minimize cultural bias and provide a more accurate cognitive measure in diverse populations.In the STT,Part B shows all numbers (from 1 to 25) twice, once in a circle and once in a square. The participants are asked to make lines alternating between circles and squares and disregarding the numbers of the alternate shapes. The scoring of the STT has several indexes: (1) time in seconds required to complete each par | ClinicalTrials.gov |
| Secondary | 1-back Task more-odd shifting Task Stroop Task | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | The 1-back task was used to explore the performance of different age groups on the memory updating task. subjects were used to investigate the relationship between physical activity and the executive function in the elderly by using the International Physical Activity Scale, 1-back Task, more-odd shifting Task and Stroop Task. E-Peime3.0 software was used to present the above paradigm, and SPSS20.0 software was used to analyze the response time and accuracy of the subjects. | ClinicalTrials.gov |
| Secondary | Timed Up and Go | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | The Timed up and go test (TUGT) was used to assess functional mobility. Participants were asked to walk at their ordinary walking speed during the tes t. They were seated at the beginning of the test and were asked to stand up from the chair, walk 3 m, turn around, return to the chair, and sit down again. The duration between rising from the chair and sitting down was measured with a stopwatch | ClinicalTrials.gov |
| Secondary | Close-eyed stepping in place | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | Prepare to draw a 20 cm x 20 cm square on the ground with chalk. The subject is required to stand in the center of the square and, upon hearing a command, perform stepping in place with eyes closed. The timing stops if the subject steps on the line or exits the square while stepping with eyes closed. The test should be conducted twice, and the longest time taken should be recorded | ClinicalTrials.gov |
| Secondary | Single-leg stance with eyes closed | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | For this test, the subject wears comfortable flat shoes, places hands on hips, and closes their eyes. They then stand on each leg separately, with the other leg bent at the knee and lifted 10cm off the ground, with the lower leg touching the standing leg (although it can be slightly apart during the test). Timing begins when the foot leaves the ground and ends if the standing foot moves, the body leans significantly, or the lifted foot touches the ground. The test is conducted 3 times, with a 1-minute rest in between, and the best result is recorded | ClinicalTrials.gov |
| Secondary | Ankle-Brachial Index (ABI) | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | Ankle-Brachial Index (ABI) is a non-invasive vascular test that assesses peripheral arterial disease by comparing blood pressure measurements in the ankles and arms. ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm. A normal ABI value is typically between 0.90 and 1.30, with lower values indicating potential arterial blockages. ABI is a crucial diagnostic tool for evaluating peripheral arterial health and identifying risks associated with reduced blood flow to the extremities. | ClinicalTrials.gov |
| Secondary | Short-Physical Performance Battery (SPPB) | This study was a cross-sectional study. Each subject was measured only once from the day of randomization to the first assessment, assessed up to 3 months | The SPPB is the National Institute on Aging's approved method of assessing muscle function in older adults. There are three components, the balance test, the gait speed test, and the chair sit-to-stand test. Asian Working Group for Sarcopenia: 2019 Consensus (AWGS) 2019 recommends SPPB score ≤9 as the cutoff for low physical performance. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Secondary outcome | ConductCognition |
| Memory Updating Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)